HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Assessment methods for aspirin-mediated platelet antiaggregation in type 2 diabetic patients: degree of correlation between 2 point-of-care methods.

AbstractAIMS:
Impaired response to antiplatelet therapy in diabetic patients results in a higher incidence of drug-eluting stent thrombosis. This study determined the prevalence of high on-aspirin (AS) platelet reactivity in type 2 diabetic patients treated with percutaneous coronary intervention (PCI) using the VerifyNow Aspirin Assay (VN) and platelet function analyzer PFA-100 (PFA-100) and analyzed the correlation between both methods.
METHODS:
Type 2 diabetic patients (100) with non-ST-elevation acute coronary syndrome who underwent PCI and Xience V drug-eluting stent implantation were included in this study. After PCI, platelet antiaggregation mediated by acetylsalicylic acid was assessed by VN and PFA-100. The degree of correlation and concordance was then determined.
RESULTS:
When assayed with VN, 7% of the patients were nonresponders to aspirin (aspirin reaction units >550), and when assayed with PFA-10, 41% were nonresponders (closure time <193 seconds). Of the patients, 4% were nonresponders to aspirin according to VN but were sensitive to aspirin according to PFA-100, and 38% were sensitive to aspirin according to VN and nonresponders according to PFA-100. Overall, 55% of the patients were aspirin-sensitive in both methods. The Spearman's coefficient between VN and PFA-100 results was r = 0.09 (P = 0.35). The kappa index value was 0.0062 (P = 0.91).
CONCLUSIONS:
There is no concordance or correlation between the VN and PFA-100 results. Therefore, the use of these analyses should be restricted to clinical research, which limits its application in clinical practice.
AuthorsJose M Cubero Gómez, María A Navarro Puerto, Juan Acosta Martínez, María I De Mier Barragán, Pastor L Pérez Santigosa, Francisco Sánchez Burguillos, Francisco Molano Casimiro, Luis Pastor Torres
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 64 Issue 1 Pg. 16-20 (Jul 2014) ISSN: 1533-4023 [Electronic] United States
PMID24553145 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet Aggregation Inhibitors
  • Aspirin
Topics
  • Aspirin (pharmacology, therapeutic use)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Drug-Eluting Stents
  • Female
  • Humans
  • Male
  • Percutaneous Coronary Intervention (methods)
  • Platelet Aggregation Inhibitors (pharmacology, therapeutic use)
  • Platelet Function Tests
  • Point-of-Care Systems
  • Prospective Studies
  • Statistics, Nonparametric

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: